You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

VFEND Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Vfend patents expire, and when can generic versions of Vfend launch?

Vfend is a drug marketed by Pf Prism Cv and is included in three NDAs.

The generic ingredient in VFEND is voriconazole. There are fourteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the voriconazole profile page.

US ANDA Litigation and Generic Entry Outlook for Vfend

A generic version of VFEND was approved as voriconazole by MYLAN PHARMS INC on April 22nd, 2010.

  Start Trial

Drug patent expirations by year for VFEND
Drug Prices for VFEND

See drug prices for VFEND

Recent Litigation for VFEND

Identify potential future generic entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.2018-06-19
MERCK SHARP & DOHME CORP. v. MYLAN LABORATORIES LIMITED2018-03-29

See all VFEND litigation

Synonyms for VFEND
(+/-)-Voriconazole
(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol
(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol
(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
(2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
137234-62-9
188416-29-7
2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol
234V629
2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-
AB0013963
AB00639948_07
AB00639948_08
AB00639948-04
AB00639948-06
AC-823
AKOS005145705
BCEHBSKCWLPMDN-MGPLVRAMSA-N
BCPP000019
BDBM50333117
C07622
C16H14F3N5O
CAS-137234-62-9
CCG-100941
CHEBI:10023
CHEMBL638
CPD000466350
CS-1227
CTK8E9205
D00578
DB00582
DRG-0301
DSSTox_CID_26485
DSSTox_GSID_46485
DSSTox_RID_81656
DTXSID5046485
FT-0082604
FT-0631154
HMS2051N09
HMS3260M22
HMS3713F12
HY-76200
I992
J-006986
J10329
JFU09I87TR
KS-0000001W
KS-1157
LS-181799
MFCD00905717
MLS000759464
MLS001424082
MLS006010028
NC00191
NCGC00164622-01
NCGC00164622-02
NCGC00164622-04
NCGC00260835-01
NSC-759888
NSC759888
Pfizer
Pharmakon1600-01502346
Q412236
RT-016239
s1442
SAM001246664
SB17419
SC-25806
SCHEMBL36233
SMR000466350
SW197571-2
SYN3012
Tox21_112241
Tox21_112241_1
Tox21_500150
UK 109496
UK-109,496
UK-109496
UNII-JFU09I87TR
UNII-USG4B1CD29 component BCEHBSKCWLPMDN-MGPLVRAMSA-N
VCZ
Vfend (TN)
VFEND I.V.
Voriconazol
Voriconazole
Voriconazole - Vfend
Voriconazole (JP17/USAN/INN)
Voriconazole [USAN:INN:BAN]
Voriconazole 2.0 mg/ml in Methanol
Voriconazole in combination with MGCD290
Voriconazole related compound A
Voriconazole related compound A RS [USP]
Voriconazole, (+/-)-
Voriconazole, >=98% (HPLC)
Voriconazole, 98%
Voriconazole, European Pharmacopoeia (EP) Reference Standard
Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material
Voriconazole, United States Pharmacopeia (USP) Reference Standard
Voriconazole, VETRANAL(TM), analytical standard
Voriconazolum
Vorikonazole
VRC
W-5208
Z2616414875
ZINC14864
Paragraph IV (Patent) Challenges for VFEND
Tradename Dosage Ingredient NDA Submissiondate
VFEND FOR SUSPENSION;ORAL voriconazole 021630 2010-10-08
VFEND INJECTABLE;INTRAVENOUS voriconazole 021267 2008-09-12
VFEND TABLET;ORAL voriconazole 021266 2008-04-14

US Patents and Regulatory Information for VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv VFEND voriconazole FOR SUSPENSION;ORAL 021630-001 Dec 19, 2003 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;INTRAVENOUS 021267-001 May 24, 2002 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv VFEND voriconazole INJECTABLE;INTRAVENOUS 021267-001 May 24, 2002   Start Trial   Start Trial
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002   Start Trial   Start Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;INTRAVENOUS 021267-001 May 24, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for VFEND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0440372 C300100 Netherlands   Start Trial PRODUCT NAME: VORICONAZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319
0440372 SPC/GB02/031 United Kingdom   Start Trial PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
0440372 02C0030 France   Start Trial PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.